Bryan M. Reasons

Insider Reports History

Location
Hayward, CA
Signature
/s/ Mark Tyndall, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Bryan M. Reasons:

Form 4 holding Director

Aclaris Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
$0
Report date
01 Jun 2024
Price
$1.26
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Societal CDMO, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
08 Apr 2024
Price
$1.10
Ownership
Direct
Form 4 holding EVP & CFO

Mallinckrodt plc

Security class
Restricted Stock Units
Shares / value
54,714
Estimated value
Report date
31 Jul 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Aclaris Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
15,750
Estimated value
Report date
01 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding EVP & CFO

Mallinckrodt plc

Security class
Ordinary Shares
Shares / value
5,114
Estimated value
Report date
01 Jan 2025
Price
$37.50
Ownership
Direct
Form 4 holding Director

Societal CDMO, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
08 Apr 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Bryan M. Reasons

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .